Ianthus Capital Holdings Inc
CNSX:IAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (1), the stock would be worth CA$0.01 (5% upside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.9 | CA$0.01 |
0%
|
| 3-Year Average | 1 | CA$0.01 |
+5%
|
| 5-Year Average | 0.9 | CA$0.01 |
+0%
|
| Industry Average | 1 | CA$0.01 |
+9%
|
| Country Average | 1.7 | CA$0.01 |
+84%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
I
|
Ianthus Capital Holdings Inc
CNSX:IAN
|
34.3m CAD | 0.9 | -0.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 9.4 | 44.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 3.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 2.9 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 3.7 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 2.9 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 2.6 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 56 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 2.7 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 1 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 2 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1 |
| Median | 1.7 |
| 70th Percentile | 3.7 |
| Max | 95 179.6 |
Other Multiples
Ianthus Capital Holdings Inc
Glance View
iAnthus Capital Holdings, Inc. engages in the provision of financing licensed cannabis cultivators, processors, and dispensaries. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2016-09-07. The Company, through its subsidiaries, owns and operates approximately 31 dispensaries and 10 cultivation and/or processing facilities in the United States. In addition, it distributes cannabis and CBD products to over 200 dispensaries and CBD products to over 2,300 retail locations throughout the United States. Its Cannabis products include biomass, products containing biomass, such as pre-rolls, cannabis infused products, such as topical creams and edibles and products containing cannabis extracts, such as vape cartridges, concentrates, live resins, wax products, oils and tinctures. Its CBD products include topical creams, tinctures and sprays and products designed for beauty and skincare.
